The health care reforms under consideration in Washington D.C. have the potential to reshape economic incentives and require medical device companies to rethink their strategies and operations. Biocom has asked a panel of experts to discuss the proposed changes and answer questions on healthcare reform and its potential impact on health insurance reimbursement for medical devices. The panel includes Jeff Bush, director of corporate reimbursement, BD Diagnostics; John Hellow of Hooper, Lundy & Bookman, Steve Danon, chief of staff for Congressman Brian Bilbray. More information and online registration is here.